Grandér/Pokrovskaja Tamm forskargrupp

This page in English

Cancerläkemedels antitumorala mekanismer och ickekodande transkript i tumörutveckling

Gruppen driver två separata projekt. I det ena projektet undersöks antitumörmekanismer hos cytokin interferon, glukokortikoider, tyrosinkinas inhibitorer samt cytostatiker med syftet att optimera behandlingsmetoder med denna substans. I ett annat projekt karaktäriserar vi nya ickekodande transkript involverade i tumörutveckling och utvärderar deras progostiska värde.

Mer information finns på den engelska sidan.

Finansiering

  • Cancerfonden (Studier över cancerläkemedels effekter och resistensmekanismer)
  • Barncancerfonden (Molekulära mekanismer för leukemiutveckling och terapisvar)
  • Stiftelsen för Strategisk Forskning, Industridoktorand (Autofagi i cancerterapi)
  • Konung Gustaf V:s Jubileumsfond (Drug development to overcome drug resistance and the Role of non-coding RNA in cancer)
  • Karolinska Institutet, KID (STAT3 as a target for cancer therapy)
  • Karolinska Institutet, KID (Comprehensive analysis of non-coding RNAs in hematological malignancies)

Katja Pokrovskaja Tamm, PI, PhD, docent
Ann-Charlotte Björklund, laboratorieassistent
Jason Tyler Serviss, MSc, doktorand
Linda Vidarsdottir, post doc
Matheus Dyczynski, doktorand
Sander Busker, doktorand
Yasmin Yu, doktorand
Elin Edsbäcker, doktorand, anknuten
Vasilios Zachariadis, MD, PhD, postdoc
Martin Enge, PhD, forskarassistent
Nathanael Johansson Andrews, doktorand

Utvalda publikationer

Identification of novel small molecules that inhibit STAT3-dependent transcription and function.
Kolosenko I, Yu Y, Busker S, Dyczynski M, Liu J, Haraldsson M, et al
PLoS ONE 2017 ;12(6):e0178844

Tumor acidosis enhances cytotoxic effects and autophagy inhibition by salinomycin on cancer cell lines and cancer stem cells.
Pellegrini P, Dyczynski M, Sbrana F, Karlgren M, Buoncervello M, Hägg-Olofsson M, et al
Oncotarget 2016 Jun;7(24):35703-35723

Cell crowding induces interferon regulatory factor 9, which confers resistance to chemotherapeutic drugs.
Kolosenko I, Fryknäs M, Forsberg S, Johnsson P, Cheon H, Holvey-Bates E, et al
Int. J. Cancer 2015 Feb;136(4):E51-61

A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells.
Johnsson P, Ackley A, Vidarsdottir L, Lui W, Corcoran M, Grandér D, et al
Nat. Struct. Mol. Biol. 2013 Apr;20(4):440-6

Proteomic screen reveals Fbw7 as a modulator of the NF-κB pathway.
Arabi A, Ullah K, Branca R, Johansson J, Bandarra D, Haneklaus M, et al
Nat Commun 2012 ;3():976

MiR-200c regulates Noxa expression and sensitivity to proteasomal inhibitors.
Lerner M, Haneklaus M, Harada M, Grandér D
PLoS ONE 2012 ;7(5):e36490

Involvement of miR17 pathway in glucocorticoid-induced cell death in pediatric acute lymphoblastic leukemia.
Harada M, Pokrovskaja-Tamm K, Söderhäll S, Heyman M, Grander D, Corcoran M
Leuk. Lymphoma 2012 Oct;53(10):2041-50

Glucocorticoid-induced cell death is mediated through reduced glucose metabolism in lymphoid leukemia cells.
Buentke E, Nordström A, Lin H, Björklund A, Laane E, Harada M, et al
Blood Cancer J 2011 Jul;1(7):e31

MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression.
Lerner M, Lundgren J, Akhoondi S, Jahn A, Ng H, Akbari Moqadam F, et al
Cell Cycle 2011 Jul;10(13):2172-83

DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1.
Lerner M, Harada M, Lovén J, Castro J, Davis Z, Oscier D, et al
Exp. Cell Res. 2009 Oct;315(17):2941-52

Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy.
Laane E, Tamm K, Buentke E, Ito K, Kharaziha P, Khahariza P, et al
Cell Death Differ. 2009 Jul;16(7):1018-29

Glucocorticoid-induced cell death is mediated through reduced glucose metabolism in lymphoid leukemia cells.
Buentke E, Nordström A, Lin H, Björklund A, Laane E, Harada M, et al
Blood Cancer J 2011 Jul;1(7):e31

Interferon alpha induces nucleus-independent apoptosis by activating extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase downstream of phosphatidylinositol 3-kinase and mammalian target of rapamycin.
Panaretakis T, Hjortsberg L, Tamm K, Björklund A, Joseph B, Grandér D
Mol. Biol. Cell 2008 Jan;19(1):41-50

Cancer och onkologiRNA